# 2026-07371: Green Light for Kids' COVID Jab Using Rare Disease Fast-Pass

2026-07371, Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; MNEXSPIKE (COVID-19 Vaccine, mRNA), is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-04-16, effective 2025-05-30; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-07371
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-07371
- Title: Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; MNEXSPIKE (COVID-19 Vaccine, mRNA)
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 20472
- Published: 2026-04-16
- Effective: 2025-05-30
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

Green Light for Kids' COVID Jab Using Rare Disease Fast-Pass

## Summary

The FDA just gave the green light to MNEXSPIKE, a COVID-19 vaccine, using a special Rare Pediatric Disease Priority Review Voucher. This means the vaccine got a faster review because it helps kids with rare diseases. The approval happened on May 30, 2025, and this move speeds up access to important treatments for children who need them most.

## Abstract

The Food and Drug Administration (FDA) is announcing the issuance of approval of a product redeeming a priority review voucher. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the issuance of priority review vouchers as well as the approval of products redeeming a priority review voucher. FDA has determined that MNEXSPIKE (COVID-19 Vaccine, mRNA), approved May 30, 2025, meets the criteria for redeeming a priority review voucher.

## Effects PRIA read

- Pediatric COVID Vaccine Approved Faster: benefit, medium. If you have a child with a rare pediatric condition, the FDA approved MNEXSPIKE (a COVID-19 mRNA vaccine) on May 30, 2025 using a Rare Pediatric Disease Priority Review Voucher. That voucher means the vaccine received a faster review so it can reach children who need it sooner.

## Related documents

- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27
- [2026-20727](https://policyrisk.com/federal-register/2026-20727): Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorgani…, 2026-10-09

## Sources
- [2026-07371 on federalregister.gov](https://www.federalregister.gov/documents/2026/04/16/2026-07371/notice-of-approval-of-product-under-voucher-rare-pediatric-disease-priority-review-voucher-mnexspike)
- [2026-07371 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-04-16/pdf/2026-07371.pdf)

## Related
- [Previous: 2026-07370, Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Re…](https://policyrisk.com/federal-register/2026-07370)
- [Next: 2026-07372, Notice of Inventory Completion: U.S. Army Corps of Engineers, Huntington Distri…](https://policyrisk.com/federal-register/2026-07372)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-07371 (as of 2026-06-08).